]>
IRCT20160215026563N2 IRCT 2019-01-14 Mashhad University of Medical Sciences Investigation of the effect of Nimodipine on the treatment of resistant cutaneous leishmaniasis investigation of the therapeutic effects of intralesional injection of Nimodipine on the treatment of resistant cases of cutaneous leishmaniasis 2018-06-27 anticipated 17 Complete https://irct.ir/trial/35911 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 resistant cases of cutaneous leishmaniasis. Intervention group: Patients who have had a complete treatment period with intralesional glucantime injections and have resistance to treatment (no clinical improvement of lesions after 12 sessions of injection) enter the study through convenience sampling. These patients receive weekly intramuscular injection of Nimodipine for 10 weeks as treatment. The amount of medication required for intralesional injection is 30 μg / ml.. Yes - There is a plan to make this available What will be shared: All data can be shared after patients are made unidentifiable. When: Data can be accessible 6 months after results are published. To whom: Data will be available for researchers in universities and other scientific institutes. Conditions: Carrying out analysis on data is permitted. Where to obtain: Data can be accessible through sending an email to the corresponding author. How to obtain: After sending a request email to the corresponding author, data will be sent in 1 month. Comments:
public Marzieh Pishgouy
Ghaem hospital, Ahmad Abad Ave
Mashhad Iran (Islamic Republic of) 9176699199 +98 51 3801 2493 Pishgouym951@mums.ac.ir Mashhad University of Medical Sciences scientific Mohammad Javad Yazdanpanah
Emam Reza hospital, Emam Reza Sq, Ebne-Sina Ave
Mashhad Iran (Islamic Republic of) 9137913316 +98 51 3802 5732 yazdanpanahmj@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Age more than 18 years; maximum lesion number is 4; duration of illness is less than one year; lesion type is dry Leishmaniasis (Clinical manifestation of urban leishmaniasis); There are no sings of lymphangitis and sporotrichoid; No more than 2 months has passed from the incidence of the lesion until wound formation; there is no widespread wound and secretion. 18 years no limit Both having other atypical forms such as lupoid-sporotrichoid-erysipeloid-zoster forms and....; patients who have had a heart attack within the last month; patients with unstable angina; patients with less than 100 spontaneous bacterial peritonitis (SBP) and consuming medications such as Azoles and Sodium Vauproat, and Macrolide and Fluoxetine due to the prohibition of Nimodipine use in these people; incidence of drug complications during treatment such as Phlebitis, hypotension, headache, severe nausea and vomiting; pregnancy; breastfeeding; the lesion is preferably not on the face. B55.1 Cutaneous leishmaniasis Treatment - Drugs Intervention group: Patients who have had a complete treatment period with intralesional glucantime injections and have resistance to treatment (no clinical improvement of lesions after 12 sessions of injection) enter the study through convenience sampling. These patients receive weekly intramuscular injection of Nimodipine for 10 weeks as treatment. The amount of medication required for intralesional injection is 30 μg / ml. Change in size and value of induration. Timepoint: Patients are evaluated every week until the end of treatment, one and a half months and three months after the end of the treatment. Method of measurement: Using caliper and measuring the diameter of lesion. Mashhad University of Medical Sciences Approved 2018-04-11 Ethics committee of Mashhad University of Medical Sciences Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah street Mashhad Razavi Khorasan Iran (Islamic Republic of)